201 related articles for article (PubMed ID: 38480884)
21. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
[TBL] [Abstract][Full Text] [Related]
22. Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer.
Yu L; Lai Q; Gou L; Feng J; Yang J
J Drug Target; 2021 Jan; 29(1):1-11. PubMed ID: 32700566
[TBL] [Abstract][Full Text] [Related]
23. New insights into small-cell lung cancer development and therapy.
Wang Y; Zou S; Zhao Z; Liu P; Ke C; Xu S
Cell Biol Int; 2020 Aug; 44(8):1564-1576. PubMed ID: 32281704
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.
Hu J; Wang Y; Zhang Y; Yu Y; Chen H; Liu K; Yao M; Wang K; Gu W; Shou T
Cancer Med; 2019 Aug; 8(9):4338-4347. PubMed ID: 31199602
[TBL] [Abstract][Full Text] [Related]
25. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
26. Origins, genetic landscape, and emerging therapies of small cell lung cancer.
Semenova EA; Nagel R; Berns A
Genes Dev; 2015 Jul; 29(14):1447-62. PubMed ID: 26220992
[TBL] [Abstract][Full Text] [Related]
27. Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases.
Meder L; König K; Fassunke J; Ozretić L; Wolf J; Merkelbach-Bruse S; Heukamp LC; Buettner R
Exp Mol Pathol; 2015 Dec; 99(3):682-6. PubMed ID: 26546837
[TBL] [Abstract][Full Text] [Related]
28. [Clinical Development of Immunotherapy for Small Cell Lung Cancer].
Yu T; Zhong D
Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):918-923. PubMed ID: 30591100
[TBL] [Abstract][Full Text] [Related]
29. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
[TBL] [Abstract][Full Text] [Related]
30. [Immunotherapy Advances in Small Cell Lung Cancer].
Xu Y; Zhan P; Song Y
Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):989-998. PubMed ID: 32752583
[TBL] [Abstract][Full Text] [Related]
31. Tracking the Evolution of Non-Small-Cell Lung Cancer.
Jamal-Hanjani M; Wilson GA; McGranahan N; Birkbak NJ; Watkins TBK; Veeriah S; Shafi S; Johnson DH; Mitter R; Rosenthal R; Salm M; Horswell S; Escudero M; Matthews N; Rowan A; Chambers T; Moore DA; Turajlic S; Xu H; Lee SM; Forster MD; Ahmad T; Hiley CT; Abbosh C; Falzon M; Borg E; Marafioti T; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Shah R; Joseph L; Quinn AM; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Dentro S; Taniere P; O'Sullivan B; Lowe HL; Hartley JA; Iles N; Bell H; Ngai Y; Shaw JA; Herrero J; Szallasi Z; Schwarz RF; Stewart A; Quezada SA; Le Quesne J; Van Loo P; Dive C; Hackshaw A; Swanton C;
N Engl J Med; 2017 Jun; 376(22):2109-2121. PubMed ID: 28445112
[TBL] [Abstract][Full Text] [Related]
32. Current and future therapeutic approaches for the treatment of small cell lung cancer.
Rossi A; Tay R; Chiramel J; Prelaj A; Califano R
Expert Rev Anticancer Ther; 2018 May; 18(5):473-486. PubMed ID: 29544351
[TBL] [Abstract][Full Text] [Related]
33.
Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
[TBL] [Abstract][Full Text] [Related]
34. Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.
Park S; Shim J; Mortimer PGS; Smith SA; Godin RE; Hollingsworth SJ; Kim HJ; Jung HA; Sun JM; Park WY; Ahn JS; Ahn MJ; Lee SH; Park K
Cancer; 2020 Sep; 126(17):4002-4012. PubMed ID: 32584426
[TBL] [Abstract][Full Text] [Related]
35. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
Bar J; Ofek E; Barshack I; Gottfried T; Zadok O; Kamer I; Urban D; Perelman M; Onn A
Lung Cancer; 2019 Dec; 138():109-115. PubMed ID: 31683093
[TBL] [Abstract][Full Text] [Related]
36. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
37. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions.
Megyesfalvi Z; Gay CM; Popper H; Pirker R; Ostoros G; Heeke S; Lang C; Hoetzenecker K; Schwendenwein A; Boettiger K; Bunn PA; Renyi-Vamos F; Schelch K; Prosch H; Byers LA; Hirsch FR; Dome B
CA Cancer J Clin; 2023; 73(6):620-652. PubMed ID: 37329269
[TBL] [Abstract][Full Text] [Related]
38. A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.
Qiu Z; Lin A; Li K; Lin W; Wang Q; Wei T; Zhu W; Luo P; Zhang J
Drug Des Devel Ther; 2019; 13():2021-2041. PubMed ID: 31417239
[TBL] [Abstract][Full Text] [Related]
39. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
[TBL] [Abstract][Full Text] [Related]
40. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
Li H; Wang H; Deng K; Han W; Hong B; Lin W
Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
